Evidence map›Paper›PMID 38622118›Full record

ArticleCell death & disease2024

Identification of a novel form of caspase-independent cell death triggered by BH3-mimetics in diffuse large B-cell lymphoma cell lines.

Nahide Yildirim, Lakshmi Sarojam, Victoria M Smith, Nadja M Pieper, Marius Anders, Ross A Jackson, Dominik C Fuhrmann, Vinzenz Särchen, Daniela Brücher, Andreas Weigert and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Nahide YildirimInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.
Lakshmi SarojamInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.
Victoria M SmithThe Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
Nadja M PieperInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.ORCID 0009-0009-3305-8587
Marius AndersInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.
Ross A JacksonThe Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
Dominik C FuhrmannFaculty of Medicine, Institute of Biochemistry I, Goethe University Frankfurt, Frankfurt am Main, Germany.ORCID 0000-0002-4902-9387
Vinzenz SärchenInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.ORCID 0000-0001-9565-2850
Daniela BrücherInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.
Andreas WeigertFaculty of Medicine, Institute of Biochemistry I, Goethe University Frankfurt, Frankfurt am Main, Germany.ORCID 0000-0002-7529-1952
Martin J S DyerThe Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
Meike VoglerInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany. m.vogler@kinderkrebsstiftung-frankfurt.de.ORCID 0000-0003-2650-586X
Goethe University Frankfurt · DEUniversity of Leicester · GB

Funding

Deutsche Krebshilfe (German Cancer Aid) 70114124Else Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation) 2018_A108Kay Kendall Leukaemia Fund (KKLF) KKL1276Wilhelm Sander-Stiftung (Wilhelm Sander Foundation) 2021.042.1
6 · The paper itself

Abstract

BH3-mimetics represent promising anti-cancer agents in tumors that rely on the anti-apoptotic function of B-Cell Lymphoma 2 (BCL2) proteins, particularly in leukemia and lymphoma cells primed for apoptosis. Mechanistically, BH3-mimetics may displace pro-apoptotic binding partners thus inducing BAX/BAK-mediated mitochondrial permeabilization followed by cytochrome c release, activation of the caspase cascade and apoptosis. Here, we describe a novel mode of caspase-independent cell death (CICD) induced by BH3-mimetics in a subset of diffuse large B-cell lymphoma (DLBCL) cells. Of note, rather than occurring via necroptosis, CICD induced immediately after mitochondrial permeabilization was associated with transcriptional reprogramming mediated by activation of c-Jun N-terminal Kinase (JNK) signaling and Activator Protein 1 (AP1). Thereby, CICD resulted in the JNK/AP1-mediated upregulation of inflammatory chemokines and increased migration of cytotoxic Natural Killer (NK) cells. Taken together, our study describes a novel mode of CICD triggered by BH3-mimetics that may alter the immune response towards dying cells.

Indexed as

Antineoplastic AgentsLymphoma, Large B-Cell, DiffuseApoptosisbcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinCaspasesCell LineHumansProto-Oncogene Proteins c-bcl-2Antineoplastic Agentsbcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinCaspasesProto-Oncogene Proteins c-bcl-2

Identifiers

PMID38622118
PMCPMC11018778
OpenAlexW4394811034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.